Related Experiment Video
Updated: Apr 27, 2026

Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
Rimonabant-induced catatonia in schizophrenia: A case report
Nalini N Reddy1, Naren P Rao1, Ganesan Venkatasubramanian1
1The Metabolic Clinic in Psychiatry, Department of Psychiatry, National Institute of Mental Health & Neurosciences, Hosur Road, Bangalore 560029, Karnataka, India.
Summary:
Patients with psychiatric illness have higher rates of mortality and medical co-morbidity related to increased rates of diabetes mellitus and cardiovascular disease. Rimonabant, a cannabinoid receptor (CB1) antagonist, is an anti-obesity agent and decreases risk for metabolic syndrome. Though there are reports of rimonabant associated with adverse psychiatric events like depression, rimonabant-induced catatonia is not reported. In this first time report, we describe a patient with schizophrenia developing catatonia possibly due to rimonabant.:
Related Concept Videos
Mania and Antimanic Drugs: Overview
Psychosis: Goals of Pharmacotherapy
Psychosis and Antipsychotic Drugs: Overview
Drug Therapy
Antianxiety Medications
REM Sleep Behavior Disorder
RBD is significantly associated with...
Positive Symptoms of Schizophrenia: Hallucinations and Delusions
Thought Disorders
Disorganized and unusual thought processes mark thought disorders in schizophrenia. One key feature is disorganized speech, where an individual's conversation includes...

